# Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT07345741** · NA · NOT_YET_RECRUITING · sponsor: **Donghua Zhang** · enrollment: 28 (estimated)

## Conditions studied

- R/R B-NHL
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL)

## Interventions

- **DRUG:** AcNK-Sup003 cell injection

## Key facts

- **NCT ID:** NCT07345741
- **Lead sponsor:** Donghua Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07345741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07345741, "Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07345741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*